zamtocabtagene autoleucel (MB-CART2019.1)

BIOLOGICAL3 trials

Sponsors

Miltenyi Biomedicine GmbH

Conditions

B-Cell NeoplasmCentral Nervous System LymphomaHigh Grade B-cell Lymphoma (HGBCL)Mantle Cell Lymphoma (MCL)Primary Mediastinal B-cell Lymphoma (PMBCL)Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaRichter Transformation

Phase 2

DALY II USA/ MB-CART2019.1 for DLBCL

RecruitingNCT04792489

Miltenyi Biomedicine GmbHCentral Nervous System Lymphoma, High Grade B-cell Lymphoma (HGBCL), Mantle Cell Lymphoma (MCL) +6

Start: 2021-05-25End: 2028-12-31Target: 315Updated: 2026-07-13

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

RecruitingNCT06508931

Miltenyi Biomedicine GmbHB-Cell Neoplasm

Start: 2025-08-04End: 2029-12-31Target: 31Updated: 2026-05-05

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

Not yet recruitingNCT07569965

Miltenyi Biomedicine GmbHMantle Cell Lymphoma (MCL)

Start: 2026-09-01End: 2030-03-01Target: 52Updated: 2026-05-06

Related Papers

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood2025-11-03

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood2024-11-056 citations

A RANDOMIZED PHASE II STUDY OF MB‐CART2019.1 COMPARED TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR ASCT – DALY 2‐EU TRIAL

Hematological Oncology2023-06-013 citations

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Blood2022-11-151 citations